Abstract:
This rapid review summarizes the latest primary research in temporomandibular joint (TMJ) injection treatment. The final literature searches were conducted on 4 January 2024. Selection was performed systematically following predefined eligibility criteria. Randomized control trials concerning the treatment of TMJ disorders with intra-articular injections were included. Studies on more invasive interventions were excluded. Quality of life, joint pain and range of mandibular mobility were assessed. Ultimately, 12 studies covering a total of 603 patients qualified. They concerned: (1) arthrocentesis (AC) and the administration of, (2) injectable platelet-rich fibrin (I-PRF), (3) platelet-rich plasma (PRP), (4) hyaluronic acid (HA), (5) non-steroidal anti-inflammatory drugs (NSAIDs), and (6) hypertonic dextrose (HD) with a local anesthetic. The dominant approach was to perform arthrocentesis before administering the appropriate injection substance (I-PRF, PRP, HA, or NSAID). Two current studies on the intra-articular administration of NSAIDs, specifically tenoxicam and piroxicam, are noteworthy. A mixture of PRP and HA was injected in another two trials. These two innovative approaches may prove to be significant directions for further research on injection treatment of TMJs.
摘要:
这篇快速综述总结了颞下颌关节(TMJ)注射治疗的最新初步研究。最终文献检索于2024年1月4日进行。根据预定的合格标准系统地进行选择。包括有关关节内注射治疗TMJ疾病的随机对照试验。排除了更多侵入性干预措施的研究。生活质量,评估关节疼痛和下颌活动度范围.最终,12项研究涵盖了总共603名合格患者。他们涉及:(1)关节穿刺术(AC)和管理,(2)可注射富血小板纤维蛋白(I-PRF),(3)富血小板血浆(PRP),(4)透明质酸(HA),(5)非甾体抗炎药(NSAIDs),和(6)使用局部麻醉剂的高渗葡萄糖(HD)。主要的方法是在施用适当的注射物质(I-PRF,PRP,HA,或NSAID)。关于NSAIDs关节内给药的两项最新研究,特别是替诺昔康和吡罗昔康,值得注意的是。在另外两个试验中注射PRP和HA的混合物。这两种创新方法可能被证明是进一步研究TMJ注射治疗的重要方向。